Google
ZVRA — ZEVRA THERAPEUTICS INC. (Healthcare >> Biotechnology)
ZVRA FAQ
What is ZVRA's P/E ratio?
ZEVRA THERAPEUTICS INC. (ZVRA) currently trades at a P/E ratio of 5.16.
What is ZVRA's ROE?
ZEVRA THERAPEUTICS INC. reports a Return on Equity (ROE) of 60.36%.
What is ZVRA's dividend yield?
ZEVRA THERAPEUTICS INC. offers a dividend yield of 0.00%.
What is ZVRA's Deepscope Quality Score?
Deepscope rates ZVRA's overall financial quality at 77 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ZVRA?
Deepscope's AI Timing Score for ZVRA is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ZVRA belong to?
ZEVRA THERAPEUTICS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 10.96
Price
0.08
(0.74%)
Day Change
|
|
|---|
ZVRA, ファンダメンタルスコアはgood ( ファンダメンタル = 77) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
平均ROEが低い
ROAの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are ok , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
66% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
73
GOOD
|
| Magic Formula Rank by ROE |
73
GOOD
|
| Magic Formula Rank by ROIC |
76
GOOD
|
| Price | 10.96 |
| PBV / Sector |
3.13 / 4.48
|
| Earning Per Share | 2.12 |
| PE / Sector |
5.16 / 16.68
GREAT
|
| PEG or PE/Growth / Sector |
-0.74 / 0.53
|
| Average 1M Daily Value |
21.27 M
GREAT
|
| Average 1W Daily Value |
23.11 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
66% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:24:03 |
| Symbol | ZVRA |
| Name | ZEVRA THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 59.12 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 643.17 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 101 Federal Street, Boston, MA, United States, 02110
Phone: 888 958 1253
Website: https://www.zevra.com
Employees: 61
Sector: Healthcare >> Biotechnology
Description: Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
